Nicardipine HCl
Catalog No.S4181 Synonyms: RS-69216
Molecular Weight(MW): 515.99
Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
Biological Activity
| Description | Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders. | |
|---|---|---|
| Targets |
|
|
| In vivo | Nicardipine (100 mg/kg) produces a significant transient decrease in retinal blood flow in cats. Nicardipine (100 mg/kg) produces a significant increase in ONH blood flow despite a significant decrease of the mean arterial blood pressure in cats, which suggests that nicardipine could have a beneficial effect on ONH tissue. [1] Nicardipine significantly reduces systolic pressure in the spontaneously hypertensive rats (SHR). Nicardipine significantly reduces the thickness of the tunica media, the media: lumen ratio and increases the luminal area, primarily at the level of small pial arteries and of intracerebral arteries in the spontaneously hypertensive rats (SHR). Nicardipine increases the number of neurones in the frontal cortex and in the occipital cortex of SHR and counters hyperplasia and hypertrophy of GFAP-immunoreactive astrocytes. Nicardipine increases the number of neurones in the CA1 field of the hippocampus and decreases the number and the size of astrocytes of the white matter and grey matter, respectively. [2] Nicardipine (40 mg/kg twice daily for 8 weeks) reduces plaque area by 49.2% in cholesterol-fed rabbits. Nicardipine (40 mg/kg) reduces cholesterol accumulation in the aortic arch by 74.5% in cholesterol-fed rabbits. [3] Nicardipine (5 mg/kg) combined with Nimodipine (80 mg/kg) and Flunarizine(80 mg/kg) results in a significant enhancement of the protective potency of either ethosuximide (50 mg/kg) or valproate (100 mg/kg) against clonic seizures in mice. [4] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 100 mg/mL (193.8 mM) |
|---|---|---|
| Water | Insoluble | |
| Ethanol | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 515.99 |
|---|---|
| Formula | C26H29N3O6.HCl |
| CAS No. | 54527-84-3 |
| Storage | powder |
| Synonyms | RS-69216 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01996436 | Recruiting | Cerebral Vasospasm | The University of Texas Health Science Center, Houston|Yale University|University at Buffalo|Thomas Jefferson University|University of Illinois at Chicago|Mayo Clinic|Wake Forest University Health Sciences|Temple University|Geisinger Clinic|Northwell Health|University of Michigan|Brigham and Womens Hospital|Lenox Hill Hospital | August 2016 | Phase 4 |
| NCT02558023 | Not yet recruiting | Hypertension|Preeclampsia | University Hospital, Strasbourg, France | September 2015 | Phase 3 |
| NCT01951950 | Completed | Brain Tumors | Northwestern University | September 2013 | Phase 1 |
| NCT01810302 | Terminated | Cerebral Vasospasm | University of Florida | August 2013 | Phase 2 |
| NCT02271191 | Completed | Spinal Stenosis | Yonsei University | May 2012 | Phase 4 |
| NCT01176565 | Terminated | Intracerebral Hemorrhage | University of Minnesota - Clinical and Translational Science Institute|National Institute of Neurological Disorders and Stroke (NINDS)|Medical University of South Carolina|Johns Hopkins University|University of Michigan|Neurocritical Care Research Network|National Cerebral and Cardiovascular Center|Japan Cardiovascular Research Foundation|Beijing Tiantan Hospital|China Medical University Hospital|University Hospital Heidelberg|Seoul National University Hospital | May 2011 | Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
